Primecap Management Co. CA Takes Position in Illumina, Inc. $ILMN

Primecap Management Co. CA bought a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 3,514,649 shares of the life sciences company’s stock, valued at approximately $617,981,000. Primecap Management Co. CA owned 2.33% of Illumina at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in ILMN. Capital World Investors lifted its position in Illumina by 0.6% during the fourth quarter. Capital World Investors now owns 20,101,173 shares of the life sciences company’s stock valued at $2,636,483,000 after purchasing an additional 124,323 shares in the last quarter. BlackRock Inc. purchased a new stake in Illumina in the 2nd quarter worth approximately $3,374,423,000. State Street Corp raised its stake in Illumina by 3.2% during the 4th quarter. State Street Corp now owns 6,190,114 shares of the life sciences company’s stock worth $811,895,000 after acquiring an additional 190,324 shares during the period. WCM Investment Management LLC lifted its holdings in Illumina by 45.5% during the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock valued at $715,579,000 after purchasing an additional 1,851,848 shares in the last quarter. Finally, AQR Capital Management LLC boosted its position in shares of Illumina by 30.3% in the fourth quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock worth $580,531,000 after purchasing an additional 1,028,099 shares during the period. 89.42% of the stock is currently owned by institutional investors.

Illumina Stock Up 0.8%

Shares of NASDAQ:ILMN opened at $224.99 on Wednesday. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. Illumina, Inc. has a 12 month low of $88.00 and a 12 month high of $226.84. The company has a 50-day moving average price of $190.35 and a 200 day moving average price of $153.78. The company has a market cap of $33.97 billion, a price-to-earnings ratio of 41.98, a PEG ratio of 3.14 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The firm had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. During the same quarter in the previous year, the business earned $1.19 EPS. The company’s quarterly revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities research analysts predict that Illumina, Inc. will post 5.36 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently commented on ILMN shares. Piper Sandler restated an “overweight” rating and issued a $225.00 price objective (up from $200.00) on shares of Illumina in a research report on Monday, August 3rd. Canaccord Genuity Group increased their price objective on shares of Illumina from $190.00 to $205.00 and gave the company a “hold” rating in a report on Monday, August 3rd. Stifel Nicolaus lifted their price objective on shares of Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Wall Street Zen upgraded shares of Illumina from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Finally, Citigroup increased their price objective on shares of Illumina from $95.00 to $113.00 and gave the company a “sell” rating in a report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $188.40.

Insider Activity

In related news, SVP Patricia Leckman sold 783 shares of the company’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $162.59, for a total transaction of $127,307.97. Following the transaction, the senior vice president directly owned 21,259 shares in the company, valued at approximately $3,456,500.81. This represents a 3.55% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 299,336 shares of the firm’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $217.96, for a total transaction of $65,243,274.56. Following the completion of the sale, the director directly owned 1,409,851 shares of the company’s stock, valued at approximately $307,291,123.96. The trade was a 17.51% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 2,095,958 shares of company stock worth $401,720,974. Insiders own 2.90% of the company’s stock.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.